<DOC>
	<DOCNO>NCT01605890</DOCNO>
	<brief_summary>The HIV-2 le common ie 1-2 million people West Africa . HIV-2 sensibility antiretroviral treatment ( ART ) compare HIV-1 . The ART strategy appropriate HIV-1 infection effective HIV-2 . Classical triple therapy include PI less effective HIV-2 . Also , choice ARTs second line treatment limit . The first line optimal treatment define prospective randomized evaluation strategy . The primary endpoint adapt specificity HIV-2 infection . The 1st step define , phase II clinical trial , whether strategy include 2 NRTIs raltegravir , alternative strategy classical triple therapy , show immunovirological response , least , good one obtain triple therapy . The hypothesis low ART response observe HIV-2 infection due low virological strength ARTs use combination 2 NRTIs raltegravir show therapeutic success least 50 % week 48 .</brief_summary>
	<brief_title>Trial Evaluating First Line Combination Therapy With Raltegravir , Emtricitabine Tenofovir HIV-2 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>age ≥18 year HIV2 mono infection , confirm ELISA Western Blot test Immunoblot , antiretroviral treatmentnaive , whatever duration indication prior treatment , indication treatment , least one follow criterion : type B C event , CD4 lymphocytes count 500/mm3 screeningvisit CD4 lymphocytes count decrease least 50 cell/µL/year last 3 year last CD4 lymphocytes count within /+ 10 % nadir , plasma HIV2 RNA load equal 100 copies/mL screeningvisit , Pneumocystis prophylaxis CD4 lymphocytes count 200/mm3 , combine toxoplasmosis prophylaxis case positive toxoplasmosis serology , French residency least one year , Written inform consent , sign participant investigator ( late screeningvisit prior study related intervention ) Affiliate beneficiary social security system ( State Medical Assistance social security scheme ) . Absence effective contraception method ( woman ) , Pregnancy , breastfeed wish pregnancy trial , Curative treatment progressive opportunistic infection compatible evaluate present study , Malignant tumorous affection require chemotherapy radiotherapy , Decompensated cirrhosis , Viral hepatitis C Metavir score F2 , Hemoglobinemia 7g/dL , polynuclear neutrophils 500/mm3 , platelet 50 000/mm3 , creatinine clearance 50 mL/mn , transaminase , alkaline phosphatase bilirubin 2.5N , Contraindication one excipients study treatment , Insulinedependent diabetes mellitus well control ( glycated haemoglobin ( HbA1C ) 7 % ) , Longterm corticosteroid treatment ( 3 week treatment ) , Judicial protection , legal guardianship , Participation therapeutic trial comprise exclusion period ongoing time screeningvisit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HIV-2</keyword>
</DOC>